EA201390613A1 - Обогащенный дейтерием расагилин - Google Patents

Обогащенный дейтерием расагилин

Info

Publication number
EA201390613A1
EA201390613A1 EA201390613A EA201390613A EA201390613A1 EA 201390613 A1 EA201390613 A1 EA 201390613A1 EA 201390613 A EA201390613 A EA 201390613A EA 201390613 A EA201390613 A EA 201390613A EA 201390613 A1 EA201390613 A1 EA 201390613A1
Authority
EA
Eurasian Patent Office
Prior art keywords
rasagiline
deuterium
enriched
deuterated
salts
Prior art date
Application number
EA201390613A
Other languages
English (en)
Inventor
Элизер Бахар
Антон Френкел
Виктор Пирятинский
Original Assignee
Тева Фармасьютикал Индастриз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45973513&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201390613(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Тева Фармасьютикал Индастриз Лтд. filed Critical Тева Фармасьютикал Индастриз Лтд.
Publication of EA201390613A1 publication Critical patent/EA201390613A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/57—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems of the carbon skeleton
    • C07C211/60—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems of the carbon skeleton containing a ring other than a six-membered aromatic ring forming part of at least one of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
    • A01N33/02—Amines; Quaternary ammonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Abstract

Изобретение относится к дейтерированному расагилину, его солям и применениям.
EA201390613A 2010-10-26 2011-10-25 Обогащенный дейтерием расагилин EA201390613A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40674010P 2010-10-26 2010-10-26
PCT/US2011/057698 WO2012058219A2 (en) 2010-10-26 2011-10-25 Deuterium enriched rasagiline

Publications (1)

Publication Number Publication Date
EA201390613A1 true EA201390613A1 (ru) 2013-11-29

Family

ID=45973513

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390613A EA201390613A1 (ru) 2010-10-26 2011-10-25 Обогащенный дейтерием расагилин

Country Status (16)

Country Link
US (2) US20120101168A1 (ru)
EP (1) EP2632254A4 (ru)
JP (1) JP2014503480A (ru)
KR (1) KR20140023872A (ru)
CN (1) CN103188933A (ru)
AU (1) AU2011320611A1 (ru)
BR (1) BR112013010308A2 (ru)
CA (1) CA2816104A1 (ru)
CL (1) CL2013001101A1 (ru)
EA (1) EA201390613A1 (ru)
IL (1) IL225852A0 (ru)
MX (1) MX2013004598A (ru)
NZ (1) NZ610526A (ru)
SG (2) SG10201508771TA (ru)
WO (1) WO2012058219A2 (ru)
ZA (1) ZA201303505B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8809310B2 (en) * 2006-02-21 2014-08-19 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
AU2007235517B2 (en) * 2006-04-03 2013-01-31 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Restless Legs Syndrome
CA2672414A1 (en) * 2006-12-14 2008-06-26 Teva Pharmaceutical Industries Ltd. Crystalline solid rasagiline base
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
CN101909438A (zh) * 2008-01-11 2010-12-08 泰华制药工业有限公司 雷沙吉兰制剂、其制备及用途
ES2389353T3 (es) * 2008-06-10 2012-10-25 Teva Pharmaceutical Industries Ltd. Cápsulas de gelatina blanda de rasagilina
JP2012532843A (ja) 2009-07-09 2012-12-20 ラティオファーム ゲーエムベーハー ラサギリンの塩およびその製剤
US20110130466A1 (en) * 2009-10-09 2011-06-02 Stefan Lorenzl Use of rasagiline for the treatment of progressive supranuclear palsy
EP2515891A4 (en) * 2009-12-22 2013-06-05 Teva Pharma 3-keto-N-propargyl-1-aminoindan
JP2013533287A (ja) 2010-07-27 2013-08-22 テバ ファーマシューティカル インダストリーズ リミティド 嗅覚機能不全の処置のためのラサギリンの使用
WO2012015946A1 (en) 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Dispersion of rasagiline citrate
JP2014534197A (ja) 2011-10-10 2014-12-18 テバ ファーマシューティカル インダストリーズ リミティド Ｒ（＋）−ｎ−メチル−プロパルギルアミノインダン
MX2014004308A (es) 2011-10-10 2014-07-24 Teva Pharma R(+)-n-formil-propargil-aminoindan.
AR092168A1 (es) 2012-08-17 2015-03-25 Teva Pharma Formulaciones parenterales de rasagilina
CN111323524B (zh) * 2020-04-08 2022-04-15 重庆华森制药股份有限公司 一种炔丙胺及其杂质的检测方法
CN115947675A (zh) * 2022-12-21 2023-04-11 博济医药科技股份有限公司 一种雷沙吉兰中间体及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
CA2574925A1 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical dosage forms including rasagiline
US20090111892A1 (en) * 2004-11-24 2009-04-30 Shulamit Patashnik Rasagiline Orally Disintegrating Compositions
JP2008531546A (ja) * 2005-02-22 2008-08-14 テバ ファーマシューティカル インダストリーズ リミティド エナンチオマー性インダニルアミン誘導体の合成のための改良されたプロセス
EP1948248A2 (en) * 2005-11-06 2008-07-30 Katz-Brull, Rachel Magnetic resonance imaging and spectroscopy means and methods thereof
US20110184071A1 (en) * 2008-06-02 2011-07-28 Vinayak Gore process for the preparation of amines
NZ589445A (en) * 2008-06-13 2013-06-28 Teva Pharma Rasagiline for parkinson's disease modification
WO2010054286A2 (en) * 2008-11-10 2010-05-14 Auspex Pharmaceuticals, Inc. Substituted hydroxyphenylamine compounds
US20100189791A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
US20100286124A1 (en) * 2009-04-10 2010-11-11 Auspex Pharmaceuticals, Inc. Prop-2-yn-1-amine inhibitors of monoamine oxidase type b
US20120156139A1 (en) * 2009-08-31 2012-06-21 Rachel Katz-Brull Isotopically labeled neurochemical agents and uses therof for diagnosing conditions and disorders

Also Published As

Publication number Publication date
JP2014503480A (ja) 2014-02-13
CA2816104A1 (en) 2012-05-03
SG189454A1 (en) 2013-05-31
AU2011320611A1 (en) 2013-06-13
CN103188933A (zh) 2013-07-03
CL2013001101A1 (es) 2013-09-06
SG10201508771TA (en) 2015-11-27
ZA201303505B (en) 2015-08-26
WO2012058219A2 (en) 2012-05-03
EP2632254A4 (en) 2015-08-05
WO2012058219A3 (en) 2012-07-26
IL225852A0 (en) 2013-06-27
MX2013004598A (es) 2013-07-17
EP2632254A2 (en) 2013-09-04
US20140364506A1 (en) 2014-12-11
US20120101168A1 (en) 2012-04-26
KR20140023872A (ko) 2014-02-27
NZ610526A (en) 2015-10-30
BR112013010308A2 (pt) 2016-07-05

Similar Documents

Publication Publication Date Title
EA201390613A1 (ru) Обогащенный дейтерием расагилин
EA201390081A1 (ru) Дейтерированный n-этил-n-фенил-1,2-дигидро-4-гидрокси-5-хлор-1-метил-2-оксохинолин-3-карбоксамид, его соли и их применение
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
CU20140025A7 (es) Pirimidinas anilladas sustituidas
CL2016001154A1 (es) Composiciones para prevenir o tratar alergias en infantes a partir de o alimentados por madres no secretoras.
CR20140376A (es) Compuestos para tratar la atrofia muscular espinal
UA114611C2 (uk) Пестицидні композиції і способи, що їх стосуються
UY34697A (es) Métodos para preparar análogos de nucleótidos
EA201590296A1 (ru) Дейтерированный ибрутиниб
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
EA201390074A1 (ru) 5-хлор-4-гидрокси-1-метил-2-оксо-n-фенил-1,2-дигидрохинолин-3-карбоксамид, его соли и применения
SG10201811017QA (en) Novel antibody frameworks
BR112015028853A2 (pt) Composição detergente com ph baixo
UY34582A (es) Anticuerpos anti-cxcr3
EA201600442A1 (ru) Мягкая фармацевтическая композиция на водной основе, содержащая тапентадол
BR112013005855A2 (pt) heteroarilas fundidas e seus usos
UY4281Q (es) Juguera
UY4223Q (es) Banco
CL2011002403S1 (es) Luminaria solar.
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
EA201301090A1 (ru) Антидоты антикоагулянтов
TR201902152T4 (tr) Metiltioninyum klorür (mtc) bulunan diaminofenotiazinyum bileşiklerinin kimyasal sentezi için yöntemler.
UY4243Q (es) Banco
CY1117740T1 (el) Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης
EA201492173A1 (ru) Дронедарон для применения при лейшманиозе, в составах и комбинациях для применения при лейшманиозе